BioNTech (BNTX) to Release Quarterly Earnings on Monday

Key Points

• BioNTech is set to release its Q2 2025 earnings on August 4th, expecting a loss of (1.38) per share and revenues of $161.26 million.
• Analysts have mixed ratings on the stock, with a consensus price target of $136.58, while institutional ownership stands at 15.52%.
• The stock was trading at $115.31 with a market cap of $27.72 billion and a notable debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Monday, August 4th. Analysts expect BioNTech to post earnings of ($1.38) per share and revenue of $161.26 million for the quarter.

BioNTech Trading Up 0.6%

NASDAQ:BNTX opened at $115.31 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.02 and a current ratio of 10.18. BioNTech has a one year low of $76.53 and a one year high of $131.49. The business's 50-day simple moving average is $107.05 and its 200 day simple moving average is $106.36. The stock has a market cap of $27.72 billion, a price-to-earnings ratio of -33.91 and a beta of 1.29.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Bank of America cut their price target on BioNTech from $127.00 to $126.00 and set a "buy" rating on the stock in a research note on Wednesday, July 16th. JPMorgan Chase & Co. dropped their price target on BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. Leerink Partners set a $112.00 price objective on BioNTech in a report on Monday, June 2nd. HC Wainwright reissued a "buy" rating and issued a $138.00 price objective on shares of BioNTech in a report on Wednesday, June 25th. Finally, Citigroup reaffirmed a "buy" rating and set a $140.00 price target (down from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $136.58.

Institutional Trading of BioNTech

A hedge fund recently raised its stake in BioNTech stock. Royal Bank of Canada grew its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 95.9% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,177 shares of the company's stock after purchasing an additional 3,514 shares during the period. Royal Bank of Canada's holdings in BioNTech were worth $653,000 as of its most recent SEC filing. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.